Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
Authors' contributions HZ and ZJ wrote and reviewed the manuscript
Clinical challenges and mitigation strategies Core clinical and research challenges With the widespread clinical use of platinum-based chemotherapeutics, long-term in vivo platinum accumulation has emerged as a critical yet underrecognized clinical challenge, serving as the core toxicological driver of impaired long-term quality of life and adverse health outcomes in cancer survivors
Cysteine may regulate blood pressure in part by acting as an antioxidant, either directly or via glutathione to reduce oxidative stress
54 AbdoSMSameh Abdel-MoezAHagar MagdyARehab HamdyMAbeer AbdallahSMohamed Abdel-AzizK
